Charles Lively, MD
Obstetrics & Gynecology · Odessa, TXNPI 1326062589
Payments from drug & device makers
Across 153 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$525
- Galderma Laboratories, L.p.$282
- Novo Nordisk$150
- Pfizer$142
- Zyla Life Sciences, Inc.$131
- plus $963 from 16 others
What the payments were for
- Food & beverage$3,325100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $1,132 |
| Lilly USA, LLC | 25 | $525 |
| Galderma Laboratories, L.p. | 5 | $282 |
| Novo Nordisk | 7 | $150 |
| Pfizer | 6 | $142 |
| Zyla Life Sciences, Inc. | 9 | $131 |
| Lupin Inc. | 5 | $123 |
| Teva Pharmaceuticals USA, Inc. | 6 | $121 |
| Idorsia Pharmaceuticals US Inc | 6 | $119 |
| Merz North America, Inc. | 3 | $100 |
| Ascend Therapeutics US, LLC | 6 | $89 |
| Mayne Pharma Commercial LLC | 9 | $85 |
| Biohaven Pharmaceuticals, Inc. | 4 | $80 |
| Novartis | 2 | $43 |
| Vertical Pharmaceuticals, LLC | 2 | $35 |
| Lundbeck LLC | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Acelrx Pharmaceuticals, Inc. | 2 | $25 |
| Merck | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $16 |
| Avion Pharmaceuticals | 1 | $13 |
How this compares
$3,325 in reported general payments places this provider in the 75th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 101 | $4,596 |
| Estradiol | 29 | $1,956 |
| Levothyroxine Sodium | 32 | $371 |
| Losartan Potassium | 12 | $183 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $105 |
| Bupropion XlBupropion Hcl | 20 | $105 |
| Amlodipine Besylate | 17 | $92 |
| Lisinopril | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Odessa
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Monica LopezFort Worth$8.1M
- Cynthia RobbinsFort Worth$7.8M
- John Paul RobertsPlano$4.9M
- Stephen StamatisWeatherford$4.5M
- Parke HedgesSan Antonio$4.2M
- Mary MartinBeaumont$2.8M
- Mark JacobsHouston$2.8M
- Dawnette PepplerArlington$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.